Revenue soared 77% year over year to $401.6 million, coming in well ahead of the $375 million to $380 million in revenue it forecast and the $382.2 million analyst consensus
The FDA maintains a public list of registered outsourcing facilities that's updated regularly
The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
Individuals who took Ozempic, Wegovy, Rybelsus, or another semaglutide medication and were later diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) or another serious optic nerve injury may qualify to file an Ozempic vision loss lawsuit
Free 2-day shipping on orders over $300
Our companion paper, Evaluating Biometric Trend Drivers: How to reflect medical breakthroughs and other drivers in forward-looking assumptions, explores the practicalities for insurers in maintaining an up-to-date view on emerging biometric trend drivers such as AOMs and provides a framework for incorporating the insured mortality impacts into insured improvement bases